RGS10 and ovarian cancer: The study by Cacan et al., consistent with our observations, demonstrated that 5-aza-CdR and TSA treatment both enhance RGS10 (an important regulator of chemoresistance in ovarian cancer) expression and cisplatin-mediated cell death significantly in A2780CP ovarian cancer cell line alone and in combination.